| REVIEW ARTICLE |
|
| Year : 2014 | Volume
: 2
| Issue : 1 | Page : 3-12 |
|
|
Pharmacological management of obesity: Past, present and future
Mohammed Habibuddin, Touseef Humaira
Drug Discovery and Development, Adept Pharma and Bioscience Excellence Private Limited, Hyderabad, Telangana, India
Correspondence Address:
Mohammed Habibuddin
Adept Pharma and Bioscience Excellence Private Limited, 10 2 289/26, 26A, Shanti Nagar, Road No. 2, Hyderabad - 500 028, Telangana
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2347-2618.137568
|
|
|
Obesity is the problem of children, adolescents and the elderly because it is a problem that affects all ages. Obesity leads to many metabolic disorders diabetes, hyperlipidemia, hypertension, angina, depression, indigestion and arthritis. There were several studies and reviews presented on the treatment modality in literature for obesity. But there are no comprehensive reviews on anti-obesity drugs till date. In the present review, we are presenting the pharmacological management of obesity. The literature search carried out using electronic search engines through PubMed, Biological Abstracts, BIOSIS PREVIEWS, Current Contents® /Clinical Medicine, Current Contents® /Life Sciences, EBSCO, ScienceDirect, Ingenta, Springer, Wiley Interscience, J-STAGE, Google scholar and Scifinder from 1990 to September 2013. Based on this search, we are presenting a brief review on pharmacological management of obesity, with a focus on the drugs used in the past, present and future. From this search, it is revealed that some of the drugs approved earlier for treating obesity were withdrawn from the market (Phentermine, Dexfenfluramine, Fenfluramine and Sibutramine). Some of the older drugs are introduced in combination form (Phentermine + Topiramate (Qnexa), Empatic, Concave). Most of the adrenergic and serotonergic drugs possesses adverse effects like increasing heart rate and hypertension. Similarly, some new drugs came into the market for treating obesity (Lorcaserin, Orlistat,) and few are in clinical trials in different phases of drug development (APD-365, CD-945,598, MK-0364, ATL-962, GT-389-255, AOD9604, Leptin, Peptide3-36, obinepitide and TM30338). The drugs that are under clinical trials were subjected for evaluating the safety and efficacy. We have to see in the future how many of these drugs are going to be available for treating obesity. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
